目的:研究增殖性糖尿病视网膜病变患者玻璃体基质细胞衍生因子(Strmalcell-derivedfactor-1,SDF-1)和血管内皮生长因子(Vascular endothelial growth factor，VECF)的浓度,及其相互作用关系。方法:酶联免疫吸附法(Enzyme-linked immunosorbent assay,ELISA)检测玻璃体内 SDF-1 和 VEGF 的含量,每个标本重复 3 次。实验组为增性糖尿病视网膜病变(Proliferalive diabeticretinopathy,PDR)的住院患者 30 例,对照组为同期行玻璃体切除术的特发性黄斑裂孔患者 12 例。结果: PDR 患者玻璃体 VECF 的平均浓度为(2865.87+387.85)pg/ml,明显高于特发性黄斑裂孔组[(142.42+21.03)pg/ml，P < 0.0001]。增殖性糖尿病视网膜病变患者玻璃体 SDF-1的含量平均为(298.40+24.57)pg/ml,对照组为(86.91+15.89)pg/ml,两组的差异具有统计学意义(P < 0.0001)。在 30 例PDR患者玻璃体内 VEGF 和 SDF-1 的含量表现为正相关(Peanson相关系数r=0.62，P < 0.001)。结论:增殖性糖尿病患者玻璃体 SDF-1 和 VECF 的含量均高于非糖尿病患者,提示 SDF-1 和 VEGF 共同参与了增殖性糖尿病视网膜病变患者病理性新生血管的形成过程。
Purpose:To investigate the levels of stromal cell-derived factor-1(SDF-1) andvascular endothelial growth factor (VEGF) in the vitreous of patients with proliferativediabetic retinopathy.
Methods: The levels of $DF-1 and VEGF in the vitreous of 30 eyes of 30 patients withproliferative diabetic retinopathy(PDR)and 12 eyes of 12 patients with idiopathicmacular hole ( MH) were measured by enzyme-linked immunosorbent assay. Vitreousfluid samples were obtained by vitrectomy.
Resuls:The vitreous concentration of VEGF was signifcantly higher in eyes with PDR(2 865.87+387.85 pg/ml) than in eyes with idiopathic macular hole (142.42+21.03 Pgml, P< 0.000 1). The vitreous level of SDF-1 was also significantly higher in eyes withPDR (298.40+24.57 pg/ml ) than in eyes with idiopathic macular hole (86.91+15.89Pg/ml, P< 0.000 1 ). The vitreous concentration of SDF-1 correlated significantly with that of VEGF in eyes with PDR( [correlation coefficient]r=0.62,P<0 .001)
Conclution:Vitreous levels of both SDF-1 and VEGF in patients with PDR aresignificantly higher than those of nondiabetic patients. SDF-1 may be correlated withVEGF in angiogenesis in PDR.
玻璃体淀粉样变性是一种罕见的眼病, 可独立发病, 也可以表现为系统性淀粉样变性的眼部受累, 常有家族史。报道 1 例遗传性玻璃体淀粉样变性患者, 中年发病, 双眼先后受累,有明确的家族史。双眼均行玻璃体切除术。术后病理检查结果显示: 玻璃体呈刚果红染色阳性, 电镜下发现纤维丝状物。对患者外周血进行 DNA 抽提, PCR 扩增, 克隆、筛选及测序等一系列基因检测, 发现转甲蛋白(Transthyretin, TTR) 存在着基因突变, 突变点 Gly83Arg, 这可能是玻璃体淀粉样变性发病的一个新的突变位点。
Vitreous amyloidosis is a rare condition that mainly occurs in Familial Amyloidotic Polyneuropathy (FAP). In some cases, it may be the only symptom without systemic disorders. One case of familial vitreous amyloidosis was reported here, with white, wispy opacities in vitreous cavity in both eyes. Pars plana vitrectomy and histopathological examination of the vitreous specimens were performed. The vitreous specimens showed typical microscopic features of amyloidosis with Congo red stain and non-branching fibrils on a transmission electron microscope. Transthyretin (TTR) gene was amplified with DNA isolated from the peripheral blood cells. Bi-directional sequencing of exon 3 showed a single base-pair substitution, which results in an amino acid substitution at position83, glycine to arginine (TTR Arg-83) . TTR Arg-83 may be a new pathologic mutation in vitreous amyloidosis.
息肉状脉络膜血管病变(polypoidal choroidal vasculopathy，PCV)是亚洲人中常见的眼底致盲性疾病，当PCV合并视网膜下出血或玻璃体积血(vitreous hemorrhage，VH)时，患者视力骤然下降，视力预后差异大。但目前聚焦于PCV合并VH的相关文献较少，因此研究和阐明PCV继发VH的治疗方法及预后具有重要的临床意义。目前临床上常选择手术干预，玻璃体切除术(pars plana vitrectomy，PPV)是临床上最常选择的一种术式。其他治疗方式包括玻璃体内注射抗血管内皮生长因子(vascular endothelial growth factor，VEGF)、眼内气体或硅油填充、眼内注射组织纤溶酶原激活剂(tissue plasminogen activator，tPA)和光动力疗法(photodynamic therapy，PDT)。PCV合并VH患者的视力预后决定因素是黄斑视功能的保留程度，也与年龄、术前视力、PCV病变部位、视网膜下出血量、视网膜脱离范围、基线黄斑中心厚度(central macular thickness，CMT)、是否出现术后并发症以及是否形成视网膜瘢痕等因素相关，目前也有研究发现视力预后与单核苷酸多态性(single nucleotide polymorphisms，SNP)相关。本文就PCV继发VH的临床特点、治疗及预后进行综述。
Polypoid choroidal vasculopathy (PCV) is a common fundus blinding disease in Asians. When PCV is associated with subretinal hemorrhage or vitreous hemorrhage (VH), patient's visual acuity decreases suddenly and the visual prognosis varies greatly. There are few relevant literatures focusing on VH secondary to PCV, so it is of great clinical significance to study and clarify the treatment methods and prognosis of VH secondary to PCV. At present, surgical intervention is often selected in clinical practice. Vitrectomy is the most commonly selected surgical procedure in clinical practice. The other treatment modalities include intravitreal injection of antivascular endothelial growth factor (VEGF), intraocular gas or silicone oil filling, intraocular injection of tissue plasminogen activator (tPA) and photodynamic therapy. The prognostic determinant of visual acuity in PCVpatients with VH is the degree of preservation of macular visual function. The prognostic is also related to age, preoperative visual acuity, PCV lesion location, amount of subretinal hemorrhage, extent of retinal detachment, baseline central macular thickness (CMT), postoperative complications and retinal scars. Recent studies also find that the prognosis of visual acuity is related to single nucleotide polymorphisms. This article reviews the clinical characteristics, treatment and visual prognosis of PCV associated with VH.
